Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of bridging versus non-bridging chimeric antigen receptor t-cell therapy in relapsed/refractory diffuse large b-cell lymphoma : A systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

GGGreeshma Gaddipati

Discussion

Loading...

Member takes

Overview

Systematic review identifies bridging chemotherapy improves overall survival in DLBCL, suggesting added benefits over non-bridging therapies.

Key Points

  • The study assesses the impact of bridging strategies on outcomes of CAR-T cell therapy in DLBCL patients.
  • Conducted a systematic search of PubMed, Embase, and Cochrane databases
  • Included studies comparing bridging therapy and non-bridging therapy in DLBCL patients
  • Evaluated primary outcomes of progression-free survival and overall survival
  • Calculated risk ratios and confidence intervals using a random-effects model.
  • Bridging therapy did not show significant improvement in progression-free survival compared to non-bridging therapy.
  • Bridging chemotherapy demonstrated better overall survival without increasing adverse events.
  • Cytokine release syndrome rates were similar across treatment groups.
  • Neurotoxicity was comparable among bridging modalities with no significant differences.

Cite This Study

Greeshma Gaddipati (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d91ahttps://doi.org/10.1182/blood-2025-7242
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcome of bridging therapy in chimeric antigen receptor T cell treatment for Relapsed/Refractory B-cell non-Hodgkin lymphoma: A retrospective study.2025
  2. 2Current evidence and strategies for bridging therapy in CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphomas2026
  3. 3Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B cell lymphoma2024 · 4 citations
  4. 4Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter2025
  5. 5Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults2025